Drug Discovery and Development

The division of the staff into two divisions of the company. Mass layoffs, work optimization and cost reduction. Crisis and downsizing of business. Reduce and save business. Keep the best employees.

As 59% fewer pharma companies cut staff in Q2 in 2026, job postings rise 15%

How Sheba Medical Center became OpenAI’s first international hospital partner

FDA issues final PDUFA meeting guidance, expands use of written responses 

Gilead and Nucleai probe why target-positive tumors can still resist ADCs

Schrödinger-BMS collaboration centers on Bunsen for trillion-scale computational drug discovery

The 50 best-funded biotech companies of 2026

New cell imaging method reveals hidden enzyme activity 

HHS seeks nominees for vaccine advisory panel with $757K estimated annual cost after almost two years without a meeting 

Novo Nordisk in the Drug Discovery & Development Pharma 50

Novo Nordisk’s ziltivekimab misses Phase 3 primary endpoint 

The 50 largest pharmaceutical companies in the world
50 of the best-selling pharmaceuticals
Pharma 50 Deep Dive: Keytruda holds the top brand slot

Today on Drug Discovery & Development

By |

How Sheba Medical Center became OpenAI’s first international hospital partner

OpenAI’s first international hospital partnership is taking shape at a giant medical center where English is not the default language and where the electronic health record does not come from Epic, the dominant U.S. EHR vendor. That institution is Sheba Medical Center, the Israel-based medical center with its own 50-plus-person AI Center within ARC, its…

By |

FDA issues final PDUFA meeting guidance, expands use of written responses 

The FDA has finalized new guidelines for meetings between the FDA and sponsors or applicants relating to the development and review of drugs or biological products under the Prescription Drug User Fee Act (PDUFA).   The FDA first published the draft guidance on Sept. 22, 2023, when it collected public comment on the guidelines. The final guidelines contain several changes from the draft, including modifying when INTERACT…

Read All Articles >

Drug Discovery and Development See More >

The division of the staff into two divisions of the company. Mass layoffs, work optimization and cost reduction. Crisis and downsizing of business. Reduce and save business. Keep the best employees.

As 59% fewer pharma companies cut staff in Q2 in 2026, job postings rise 15%

2022 was a big year for layoffs in biopharma. So were the next three. Novartis, for instance, outlined plans to cut up to 8,000 jobs in 2022, after pharmaceutical industry job cuts jumped 280% in 2021. Biogen followed in 2023 with a “Fit for Growth” program that put roughly 1,000 roles on the block. Bristol…

Sponsored Content See More >

Accelerating life sciences with AI
 This case study is sponsored by Infor. Artificial intelligence can revolutionize clinical interoperability by building bridges across data silos. Machine…

Genomics/Proteomics See More >

New cell imaging method reveals hidden enzyme activity 

Negative biosensors have often been unusable because, as the sensors lose signal when activity is detected, regions of high enzyme activity can look identical to regions with no activity. Researchers at the University of Illinois Chicago have solved this problem with a new cell imaging method that allows scientists to see previously hidden enzyme activities by flipping the optical readout of…

Infectious Disease See More >

Oncology See More >

As chemo overtreatment comes into focus, Atossa bets on tamoxifen’s active form 

As evidence mounts that some hormone receptor-positive, HER2-negative breast cancer patients are being overtreated with chemotherapy, researchers are working to identify which patients can safely avoid it, and to expand the treatment options available to those who can. Atossa Therapeutics thinks endoxifen, the active metabolite behind tamoxifen, could be an important addition to that toolkit.  …

Search Drug Discovery & Development